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Mitochondrial survivin inhibits apoptosis  
and promotes tumorigenesis
Takehiko Dohi, Elena Beltrami, Nathan R. Wall, Janet Plescia, and Dario C. Altieri
Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Evasion of apoptosis is a hallmark of cancer, but the molecular circuitries of this process are not understood. 
Here we show that survivin, a member of the inhibitor of apoptosis gene family that is overexpressed in cancer, 
exists in a novel mitochondrial pool in tumor cells. In response to cell death stimulation, mitochondrial sur-
vivin is rapidly discharged in the cytosol, where it prevents caspase activation and inhibits apoptosis. Selective 
targeting of survivin to mitochondria enhances colony formation in soft agar, accelerates tumor growth in 
immunocompromised animals, and abolishes tumor cell apoptosis in vivo. Therefore, mitochondrial survivin 
orchestrates a novel pathway of apoptosis inhibition, which contributes to tumor progression.
Introduction
Deregulation of apoptosis is thought to invariably occur in 
human cancer, and to facilitate the acquisition of deleteri-
ous cancer traits (1), including loss of tumor suppressor genes, 
angiogenic changes, and immortalization (2). Among the regula-
tors of apoptosis implicated in cancer cell survival, Bcl-2 family 
proteins (3) act at the mitochondrion (4) to control the release 
of apoptogenic proteins, notably cytochrome c and Smac (5), 
whereas members of the inhibitor of apoptosis (IAP) gene family 
function as endogenous inhibitors of caspases (6), the enzymatic 
effectors of apoptosis (7).
Survivin is a bifunctional IAP that has been implicated in pro-
tection from apoptosis and regulation of mitosis (8). Although an 
essential role of survivin at cell division has been linked to centro-
somal function (9), metaphase and anaphase microtubule assem-
bly (10, 11), and spindle checkpoint regulation (12), the mecha-
nism by which survivin inhibits apoptosis has remained elusive (8). 
In particular, it has been debated whether survivin has a genuine 
function in apoptosis inhibition independently of its role as a mas-
ter regulator of mitosis, and whether this is important in disease 
pathogenesis. Validating a cytoprotective mechanism of survivin 
has become a priority because of the dramatic exploitation of this 
pathway in human tumors (13), its frequent association with unfa-
vorable disease outcome (14, 15), and the recent identification of 
molecular antagonists of survivin that are approaching clinical 
testing in cancer patients (8).
In this study, we asked whether subcellular compartmentaliza-
tion of survivin could participate in cytoprotection, and whether 
this pathway has a direct role in tumor establishment and pro-
gression. We identified a novel pool of survivin that localizes to 
mitochondria and is rapidly released in the cytosol in response to 
apoptotic stimuli. In turn, mitochondrially released survivin sup-
presses caspase processing and enhances tumorigenesis in vivo.
Results
Identification of mitochondrial survivin. Because of its distribution 
among multiple subcellular compartments (16), we investigated 
whether survivin could also localize to mitochondria, an organ-
elle with a central role in cell death pathways (4). A pool of sur-
vivin was found in purified cytosolic extracts of various tumor 
cell lines (Figure 1A), in agreement with previous observations 
(16). In addition, a pool of survivin was present in isolated 
mitochondrial fractions of tumor cells and colocalized with the 
reactivity of the mitochondrial proteins Smac and Cox-4, but 
not cytoplasmic Aurora A (Figure 1A). Next, we asked whether 
mitochondrial localization of survivin was a feature of trans-
formed cells or was also observed in normal tissues. For these 
experiments, we prepared extracts from normal tissues known 
to express endogenous survivin and analyzed its distribution in 
cytosolic or mitochondrial fractions. Cytosolic extracts isolated 
from normal testis, liver, and spleen contained endogenous sur-
vivin, by immunoblotting (Figure 1B). In contrast, survivin was 
not detected in isolated mitochondrial fractions of the same 
tissues (Figure 1B). In immunoelectron microscopy experi-
ments, analysis of MCF-7 cell pellets with a nonimmune IgG 
revealed negligible accumulation of gold particles (Figure 1C). 
In contrast, analysis of whole cell pellets (Figure 1D) or isolated 
mitochondrial fractions (Figure 1E) revealed staining for sur-
vivin in close proximity to the mitochondrial membrane(s), and 
colocalization with the reactivity of an antibody to Smac (Figure 
1E). Quantification of 19 individual electron microscopy fields 
containing an average of 2.9 mitochondria each revealed that 
94% of mitochondria examined exhibited dual localization of 
survivin and Smac, with comparable accumulation of gold par-
ticles per each marker (Table 1).
We next used a biochemical approach to map more precisely 
the submitochondrial topography of survivin. Treatment of 
mitochondrial pellets with proteinase K resulted in concentra-
tion-dependent loss of Bcl-2 (Figure 2A), which localizes to the 
outer mitochondrial membrane (3). In contrast, proteinase K 
treatment did not reduce survivin levels in mitochondria (Figure 
2A). Conversely, proteinase K digested both Bcl-2 and survivin in 
isolated cytosolic extracts, confirming comparable susceptibility 
of both proteins to proteolysis (Figure 2A). We next permeabilized 
the outer mitochondrial membrane with digitonin (17) and 
looked for potential changes in survivin distribution. Digitonin 
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treatment resulted in concentration-dependent relocalization 
of survivin from mitochondrial pellets into supernatants (Fig-
ure 2B). This was also associated with release of Smac (18) from 
mitochondrial pellets into supernatants, whereas the localiza-
tion of nonextractable mitochondrial Hsp70 was unaffected by 
digitonin treatment (Figure 2B). Collectively, these data demon-
strate that a novel pool of survivin localizes to mitochondria in 
tumor cells but not in normal tissues and is compartmentalized 
in the intermitochondrial membrane space.
Stress-response modulation of mitochondrial survivin. We next asked 
whether cellular stress stimuli influenced the expression and/or 
localization of the mitochondrial pool of survivin. Exposure of 
HeLa cells to hypoxia (∼1% O2) caused a dramatic upregulation 
of the IAP family protein cIAP2 (Figure 3A), in agreement with 
previous observations (19). Hypoxia also increased survivin levels 
approximately threefold, by immunoblotting (Figure 3A). Analy-
sis of isolated subcellular fractions demonstrated that hypoxia-
induced upregulation of survivin occurred exclusively in the 
mitochondrial pool with minimal changes in cytosolic survivin 
levels (Figure 3B). To begin to determine the mechanism(s) of 
survivin modulation by hypoxia, we examined changes in protein 
levels in cycloheximide block experiments. Cyclo-
heximide treatment resulted in time-dependent 
turnover of endogenous survivin levels in HeLa cells, 
by immunoblotting (Figure 3C). Conversely, hypoxic 
HeLa cells exhibited stabilization of survivin levels 
over a 6-hour time interval, as compared with nor-
moxic cultures (Figure 3C). In control experiments, 
no significant decrease of cell viability was observed 
6 hours after hypoxia (data not shown). Finally, treat-
ment of MCF-7 cells with nonapoptotic concentra-
tions of the DNA-damaging agent adriamycin also 
resulted in selective expansion of mitochondrial sur-
vivin, with no significant changes in cytosolic sur-
vivin levels (Figure 3D).
Loss of mitochondrial survivin influences cell death. To begin to probe 
the functional role of mitochondrial survivin, we studied a rat 
insulinoma cell line, INS-1, in which survivin was found almost 
exclusively in the cytosol, but not in purified mitochondrial frac-
tions (Figure 4A). When transduced with a replication-deficient 
adenovirus (pAd) encoding WT survivin (pAd-Survivin), INS-1 
cells exhibited increased survivin expression in the cytosol, 
but not in mitochondria (Figure 4A). Conversely, MCF-7 cells 
expressed endogenous survivin in cytosolic and mitochondrial 
fractions, and both pools were coordinately increased by 
transduction with pAd-Survivin (Figure 4A). Transduction of 
MCF-7 cells with pAd-Survivin inhibited staurosporine-induced 
cell death by 65–70% (Figure 4B). In contrast, pAd-Survivin did 
not reverse apoptosis in INS-1 cells (Figure 4B). In control experi-
ments, both INS-1 and MCF-7 cells expressed comparable levels 
of transduced survivin (Figure 4B, inset).
To determine whether the lack of mitochondrial survivin resulted 
in increased sensitivity to apoptosis, we challenged INS-1 or MCF-7 
cells with suboptimal doses of cell death stimuli. Concentrations of 
staurosporine (0.1 μM) or UVB (50 joules per square meter [J/m2]) 
that did not reduce the viability of MCF-7 cells resulted in extensive 
Figure 1
Mitochondrial localization of survivin. (A) Survivin localization in tumor cell lines. Cytosolic (left panel) or mitochondrial (right panel) extracts 
from the indicated tumor cell lines were analyzed by immunoblotting. MW, molecular weight. (B) Subcellular fractionation of normal tissues. 
Mitochondrial (M) or cytosolic (C) fractions extracted from normal testis, spleen, and liver or unfractionated HeLa cell extracts were analyzed 
by immunoblotting. Cox-4 was used as a mitochondrial marker. (C–E) Immunoelectron microscopy. Mitochondrial pellets (C and E) isolated 
from MCF-7 cells or whole MCF-7 cell extracts (D) were stained with nonimmune IgG (C) or an antibody to survivin (D) followed by colloidal 
gold-conjugated secondary IgG. Isolated mitochondrial pellets (E) were simultaneously stained with antibodies to survivin (12 nm diameter gold 
particles) and Smac (6 nm diameter gold particles). Magnification, ×53,000 (C and D), ×104,000 (E).
Table 1
Quantification of survivin-Smac mitochondrial colocalization by electron 
microscopy
Total no.  Smac+  Survivin+  Average survivin  Average Smac  
mitochondria mitochondria mitochondria particles per  particles per  
   mitochondrion  mitochondrion  
   (12 nm diameter) (6 nm diameter)
56 56/56 (100%) 53/56 (94%) 6.5 ± 4.1 5.9 ± 2.6
Nineteen individual electron microscopy fields containing a total of 56 mitochondria (2.9 
mitochondria per field) were analyzed for colocalization of survivin gold particles (12 nm 
diameter) or Smac gold particles (6 nm diameter).
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apoptosis of INS-1 cells (Figure 4C). In reciprocal experiments, we 
used RNA interference (RNAi) to acutely knock down survivin lev-
els in INS-1 or MCF-7 cells and analyzed apoptosis and cell cycle 
progression (20). A survivin-derived double-stranded RNA (dsRNA) 
oligonucleotide (S4) ablated survivin levels in cytosolic and nuclear 
fractions of both MCF-7 and INS-1 cells, whereas a control dsRNA 
sequence (VIII) was without effect (Figure 4D and data not shown) 
(20). In control experiments, no phosphorylation of eIF2α was 
observed in RNAi-treated cells (Figure 4D). RNAi ablation of sur-
vivin in MCF-7 cells resulted in a dual phenotype of apoptosis and 
mitotic defects with polyploidy, by DNA content analysis and flow 
cytometry (Figure 4E), in agreement with previous observations 
(20). Although loss of survivin in INS-1 cells also caused mitotic 
defects predominantly seen as a G2/M block, this was not associated 
with significantly enhanced cell death, as compared with death of 
cells transfected with control dsRNA (VIII) (Figure 4E).
Mitochondrial survivin inhibits apoptosis. To further investigate a 
cytoprotective function of mitochondrial survivin, we engineered 
INS-1 cells to stably express WT survivin (Surv) or mitochondrially 
targeted survivin (MT-S), survivin targeted to mitochondria by the 
cytochrome c mitochondrial import sequence and containing GFP 
as a marker (INS-1/MT-S). By fluorescence microscopy, INS-1/ 
MT-S cells exhibited perinuclear GFP expression consistent with 
mitochondrial localization (see below). Staurosporine treatment 
of parental INS-1 cells, or INS-1 cells stably transfected with 
mitochondrially targeted GFP (INS-1/MT-GFP), caused caspase-
dependent cell death by multiparametric DEVDase activity (Fig-
ure 5A). Stable expression of Surv in INS-1 cells was unable to 
counteract staurosporine-induced apoptosis (Figure 5A). In con-
trast, mitochondrial targeting of survivin in INS-1/MT-S cells 
inhibited staurosporine-induced apoptosis and increased 5- to 
16-fold the percentage of viable cells, by multiparametric flow 
cytometry (Figure 5A).
We next tested the effect of mitochondrially targeted survivin on 
proteolytic processing of effector and initiator caspases. Exposure 
of INS-1/MT-GFP cells to staurosporine resulted in time-depen-
dent proteolytic cleavage of proform caspase-3 and caspase-9 
to generate active fragments of 17 kDa and 19 kDa (Figure 5B), 
and 37 kDa (Figure 5C), respectively. Conversely, expression of 
mitochondrial survivin in stably transfected INS-1 (INS-1/MT-S) 
cells suppressed the generation of active caspase-3 (Figure 5B) 
and caspase-9 (Figure 5C) at the same time intervals examined. To 
Figure 2
Topography of mitochondrial survivin. (A) Sensitivity to proteinase K. 
Mitochondrial or cytosolic fractions were treated with the indicated con-
centrations of proteinase K and analyzed by immunoblotting. Lower 
panel: Quantification of Bcl-2 or survivin proteolysis by proteinase 
K treatment. (B) Permeabilization of mitochondrial membrane. 
Mitochondrial fractions were treated with the indicated increasing con-
centrations of digitonin, and pellets (P) or supernatants (S) were ana-
lyzed by immunoblotting. mt-Hsp70, mitochondrial Hsp70.
Figure 3
Modulation of mitochondrial survivin during the cellular stress response. 
(A) Regulation of survivin by hypoxia. HeLa cells were exposed to 
hypoxia, and analyzed by immunoblotting followed by densitometry. 
N, normoxic cultures; H, hypoxic cultures. (B) Subcellular fractionation. 
Cytosolic or mitochondrial fractions from HeLa cells were exposed to 
hypoxia, and analyzed by immunoblotting. (C) Cycloheximide block. 
Normoxic or hypoxic HeLa cells were treated with cycloheximide, and 
analyzed by immunoblotting at the indicated time intervals. Lower panel: 
β-Actin–normalized densitometric quantification of differential survivin 
stability in control versus hypoxic conditions. (D) Modulation by DNA 
damage. Untreated (None) or MCF-7 cells treated with nonapoptotic 
concentrations of adriamycin (Adriam) were fractionated in cytosolic 
and mitochondrial fractions, and analyzed by immunoblotting.
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further distinguish between caspase-dependent and -independent 
cell death modulated by mitochondrial survivin, we exposed dif-
ferentially transfected INS-1 cells to staurosporine in the presence 
or absence of a broad-spectrum caspase inhibitor, z-Val-Ala-Asp 
(OMe)-fmk (zVAD-fmk). INS-1/MT-S cells were protected against 
apoptosis over a wide range of staurosporine 
concentrations, in a reaction that was not fur-
ther enhanced by zVAD-fmk (Figure 5D). Con-
versely, staurosporine-induced apoptosis in 
INS-1 or INS-1/MT-GFP cells was inhibited by 
50–75% by zVAD-fmk (Figure 5D), suggesting 
that mitochondrial survivin selectively protect-
ed against caspase-dependent cell death.
We next generated pAds encoding either MT-GFP 
(pAd-MTGFP) or hemagglutinin-tagged (HA) 
MT-S (pAd-MTS). Transduction of INS-1 cells 
with pAd-MTS resulted in selective accumu-
lation of survivin in mitochondrial, but not 
cytosolic, extracts (Figure 6A). This was associat-
ed with strong inhibition of apoptosis induced 
by UVB, serum deprivation, or staurosporine, by 
hypodiploid DNA content and flow cytometry 
(Figure 6B). In contrast, transduction of INS-1 
cells with pAd-MTGFP did not reverse apoptosis 
induced by the various cell death stimuli (Fig-
ure 6B). We next asked whether selective expan-
sion of mitochondrial survivin was sufficient 
to inhibit apoptosis. Transduction of MCF-7 
cells with pAd-Survivin resulted in increased 
expansion of both cytosolic and mitochondrial 
survivin, and inhibition of staurosporine-
induced apoptosis (Figure 6C). By compari-
son, pAd-MTS resulted solely in expansion of 
mitochondrial, not cytosolic, survivin levels and 
was equally as effective as pAd-Survivin at sup-
pressing staurosporine-induced apoptosis (Fig-
ure 6C). In control experiments, transduction of 
MCF-7 cells with pAd-MTGFP did not reduce 
staurosporine-mediated cell death (Figure 6C).
Release of mitochondrial survivin during apoptosis 
antagonizes caspase-9 generation. To begin to iden-
tify a mechanistic role of mitochondrial survivin 
in cytoprotection, we first monitored changes 
in permeability transition, i.e., the release of 
mitochondrial apoptogenic proteins following 
cell death stimulation (5). Stable expression of 
mitochondrially targeted survivin in INS-1/
MT-S cells did not reduce the cytoplasmic accu-
mulation of cytochrome c in response to stau-
rosporine, as compared with cultures express-
ing mitochondrially targeted GFP (Figure 7A). 
Similar results were obtained with analysis of 
Smac in differentially transfected INS-1 cells fol-
lowing induction of apoptosis (data not shown). 
In contrast, treatment of INS-1/MT-S with stau-
rosporine resulted in redistribution of the GFP 
signal from a punctate, perinuclear pattern 
observed in resting cells to a diffuse cytoplasmic 
localization (Figure 7B), suggestive of release of 
mitochondrial survivin. Fluorescence analysis 
of 264 individual stably transfected INS-1/MT-S cells revealed that 
staurosporine treatment resulted in translocation of the GFP signal 
from mitochondria to the cytosol in 93.3% ± 1.1% of the cell popula-
tion examined. To further quantify the dynamics of mitochondrial 
release of survivin during apoptosis, single-cell fluorescence-analy-
Figure 4
Participation of mitochondrial survivin in cell death. (A) Defective mitochondrial import of sur-
vivin in INS-1 cells. INS-1 (upper panel) or MCF-7 (lower panel) cells were left untreated 
(None) or transduced with pAd-Survivin, and isolated mitochondrial or cytosolic fractions were 
analyzed by immunoblotting. (B) Cytoprotection. INS-1 or MCF-7 cells were transduced with 
pAd-GFP or pAd-Survivin, treated with staurosporine, and analyzed for hypodiploid DNA 
content. Data are the mean ± SEM of 3 independent experiments. Inset: Immunoblotting of 
survivin in transduced INS-1 or MCF-7 cells at the indicated time intervals. (C) Differential 
sensitivity to apoptosis. INS-1 or MCF-7 cells were treated with suboptimal concentrations 
of staurosporine (STS) or UVB and analyzed for nuclear morphology of apoptosis by DAPI 
staining. Data are the mean ± SD of 2 independent experiments. (D) RNAi knock-down. INS-1 
or MCF-7 cells were transfected with dsRNA oligonucleotides to survivin (S4) or control (VIII), 
and analyzed by immunoblotting. (E) Cell cycle analysis. INS-1 or MCF-7 cells transfected 
with control or survivin dsRNA oligonucleotides were analyzed for cell cycle distribution by 
flow cytometry. The percentage of cells with hypodiploid (Sub-G1) DNA content is indicated.
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sis experiments were carried out. Determination of fluorescence 
intensity in individual areas corresponding to mitochondrial (Fig-
ure 7C, yellow squares) or cytosolic (Figure 7C, gray circles) regions 
demonstrated that staurosporine caused loss of mitochondrial GFP 
signal (1,475 ± 30.3 versus 980 ± 19, P < 0.0001, n = 16), which was 
associated with a parallel increase in cytosolic fluorescence (628 ± 21 
versus 887 ± 14.4, P < 0.0001, n = 14).
We next studied the time course of release of mitochondrial 
survivin during cell death in isolated cytosolic or mitochondrial 
fractions. In these experiments, staurosporine induced a rapid 
depletion of mitochondrial survivin, which was reduced by about 
70% 4 hours after induction of apoptosis and was completely 
discharged by 12–18 hours (Figure 7D). This coincided with 
increased accumulation of survivin in isolated cytosolic extracts 
at the same time intervals (Figure 7D) and thus agrees with the 
fluorescence analysis reported above.
To determine the requirements of cytoprotection by mitochondrial 
survivin, we studied modulation of caspase-9 cleavage in transduced 
MCF-7 cells. Staurosporine treatment of MCF-7 cells transduced 
with pAd-MTGFP resulted in time-dependent cleavage of 46-kDa 
proform caspase-9 and generation of an active, 37-kDa caspase-9 
fragment (Figure 8A). In contrast, transduction with pAd-MTS 
both delayed and attenuated the generation of active caspase-9 in 
staurosporine-treated MCF-7 cells (Figure 8A). Because survivin 
can associate with mitochondrial Smac (21), we asked whether cyto-
protection by mitochondrial survivin involved binding and seques-
tration of Smac, which would be expected to relieve its inhibitory 
function on XIAP suppression of caspases (18). A specific interac-
tion between survivin and Smac was demonstrated in vitro and in 
vivo (data not shown), in agreement with published data (21). How-
ever, transduction of MCF-7 cells with pAd-MTS did not affect the 
amount of Smac associated with XIAP during staurosporine-induced 
apoptosis, by coimmunoprecipitation and immunoblotting (Figure 
8B). In control experiments, immune complexes precipitated by 
nonimmune IgG did not contain XIAP or Smac (Figure 8B).
Role of mitochondrial survivin in tumorigenesis. To determine whether 
the distinct subcellular pools of survivin were differentially involved 
in cellular transformation, we studied the ability of differentially 
transfected INS-1 cells to form colonies in soft agar, i.e., anchorage-
independent cell growth. INS-1 cells expressing MT-GFP exhibited a 
limited degree of colony formation in soft agar over a 2-week interval 
(Figure 9, A and B). Expression of MT-S in INS-1 cells resulted in an 
approximately threefold increase in colony formation, as compared 
with expression of MT-GFP in INS-1 cells (Figure 9, A and B). In 
contrast, expression of cytosolic survivin that cannot be transported 
to mitochondria (INS-1/Surv) nearly completely abolished colony 
formation in soft agar (Figure 9, A and B).
We next injected differentially transfected INS-1 cells in 
immunocompromised mice and studied the kinetics of tumor 
formation. Tumors formed by INS-1/MT-GFP cells exhibited 
delayed onset and a flattened growth rate that did not signifi-
cantly change during the last 3 weeks of examination (Figure 
9C). Conversely, INS-1 cells expressing mitochondrially tar-
geted survivin (INS-1/MT-S) gave rise to solid tumors charac-
terized by early onset and steady exponential growth rate (Fig-
ure 9C). Stable expression of non-mitochondrially-targeted 
cytosolic survivin in INS-1 cells was associated with strong 
inhibition of tumor growth in immunocompromised animals 
Figure 5
Mitochondrial targeting of survivin in INS-1 cells inhibits apoptosis. (A) Cytoprotection in stable transfectants. Parental INS-1 cells or INS-1 cells 
stably transfected with Surv, MT-GFP, or MT-S were treated with staurosporine and analyzed for caspase-3 and caspase-7 activity (DEVDase 
activity, green fluorescence) and plasma membrane integrity (propidium iodide, red fluorescence), by multiparametric flow cytometry. The 
percentage of cells in each quadrant is indicated. (B) Caspase-3 cleavage. INS-1 cells expressing MT-GFP or MT-S were treated with stauro-
sporine and analyzed at the indicated time intervals by immunoblotting. The position of active caspase-3 bands of 17 and 19 kDa is shown. (C) 
Caspase-9 cleavage. The experimental conditions were as in B except that samples were analyzed for generation of 37-kDa active caspase-9 
fragments by immunoblotting. (D) Inhibition of caspase-dependent apoptosis. Parental INS-1 cells or INS-1 cells stably expressing MT-GFP or 
MT-S were treated with the indicated concentrations of staurosporine in the presence or absence of zVAD-fmk, and scored for nuclear morphol-
ogy of apoptosis by DAPI staining. Data are the mean ± SEM of 3 independent experiments.
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(Figure 9C); this was similar to the findings regarding forma-
tion of colonies in soft agar (Figure 9, A and B). Histologically, 
tumors formed by INS-1 cells had neuroendocrine appearance 
and exhibited an extensive network of vascular sinusoids filled 
with blood (Figure 9D). Tumor cell proliferation as detected 
by Ki67 labeling (Figure 9D) was indistinguishable in tumors 
formed by INS-1 cells expressing mitochondrially targeted GFP 
or non-mitochondrially-targeted, cytosolic survivin (INS-1/
Surv) (Figure 9E). Conversely, INS-1/MT-S tumors revealed a 
higher mitotic index (P = 0.031) as compared with INS-1/Surv 
tumors (Figure 9E). Quantification of internucleosomal DNA 
fragmentation by TUNEL staining (Figure 9D) revealed that 
expression of mitochondrially targeted survivin in INS-1/MT-S 
tumors resulted in nearly complete suppression of apoptosis in 
vivo (P = 0.0001), as compared with that in INS-1/Surv or INS-1/ 
MT-GFP tumors (Figure 9F). When compared with INS-1/ 
MT-GFP tumors, tumors expressing non-mitochondrially-
targeted, INS-1/Surv resulted in a considerably increased 
(P = 0.0003) apoptotic index (Figure 9F), which may explain the 
reduction in colony formation (Figure 9, A and B) and the slower 
growth rate of these tumors in vivo (Figure 9C).
Discussion
In this study, we have uncovered a novel pathway of apoptosis inhi-
bition centered on the compartmentalization of the IAP protein 
survivin to mitochondria. Dynamically expanded in response to 
cellular stress stimuli, and rapidly released in the cytosol following 
full-blown apoptotic stimulation, mitochondrial survivin exerts 
cytoprotection by preventing the activation of initiator caspase-9. 
This pathway has profound repercussions for tumor cell viability, 
as expression of mitochondrial survivin is sufficient to promote 
anchorage-independent cell growth, ablate tumor cell apoptosis 
in vivo, and sustain exponential tumor growth.
Since its discovery in 1997 (22), survivin has attracted attention 
as a unique member of the IAP gene family with a potential dual 
role in apoptosis inhibition and regulation of mitosis (8). The role 
of survivin in regulation of mitosis has recently become better 
understood, and linked to multiple spindle microtubule functions 
and mitotic checkpoints (8). In contrast, despite extensive experi-
mental evidence in vitro, and in transgenic animals in vivo (8), the 
precise mechanism(s) by which survivin interferes with apoptosis 
has not been elucidated. The evidence presented here defines a 
novel antiapoptotic pathway mediated by survivin, functionally 
separable from its role in mitosis. Cytoprotection by survivin is 
more selective than that by other IAPs (6) and is specifically target-
ed at the initiation of mitochondrial apoptosis to prevent caspase-9 
activation. This is consistent with the formation of a survivin–
caspase-9 complex in vivo (23), the requirement of apoptosome 
components Apaf-1 and caspase-9 in the survivin pathway (24), 
and the ability of survivin to prevent incorporation of caspase-9 
into a functional apoptosome (25). Although survivin may still 
oppose death receptor–initiated apoptosis, this is likely to occur in 
a cell type–specific fashion, in which mitochondrial amplification 
is required for effective execution of cell death (26).
Several independent lines of evidence demonstrated that sur-
vivin occurs in an abundant mitochondrial pool, localized to 
a digitonin-sensitive compartment in the inter–mitochondrial 
membrane space. The existence of a novel subcellular localization 
of survivin is consistent with the dynamic nature of this protein 
and with its distribution among multiple subcellular pools that are 
independently regulated, differentially posttranslationally modi-
fied, and uniquely immunoreactive (16). In mammalian cells, the 
mitochondrion has emerged as a central orchestrator of apoptosis 
(4, 5), by providing a specialized microenvironment for a multi-
Figure 6
Adenoviral targeting of survivin to mitochondria inhibits apoptosis. 
(A) Subcellular localization. INS-1 cells were infected with pAd-MTS, 
and isolated mitochondrial or cytosolic fractions were analyzed by 
immunoblotting. The position of endogenous or transduced (HA-MTS) 
survivin is indicated. (B) Cytoprotection by adenoviral transduction. 
INS-1 cells transduced with pAd-MTGFP or pAd-MTS were treated 
with UVB, exposed to serum starvation, or treated with staurosporine, 
and analyzed for DNA content by flow cytometry. Samples labeled as 
INS-1 were untreated cultures. The percentage of cells with hypodiploid 
(apoptotic) DNA content is indicated for each condition tested. (C) 
Mitochondrial survivin is sufficient for cytoprotection. MCF-7 cells 
were transduced with pAd-MTGFP, pAd-Survivin, or pAd-MTS, treat-
ed with staurosporine, and analyzed for hypodiploid DNA content and 
immunoblotting of whole cell extracts (W), mitochondrial, or cytosolic 
fractions. The percentages of cells with hypodiploid (apoptotic) DNA 
content were 47% (nontransduced cultures, data not shown), 40% 
(pAd-MTGFP), 25% (pAd-Survivin), and 29% (pAd-MTS).
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plicity of cell death regulators (18, 27). A localization of certain 
IAPs to mitochondria has also been reported, and cIAP2 and XIAP 
were found in mitochondrial extracts of lung cancer cell lines, 
whereas cIAP1 became recruited to mitochondria in response to 
ionizing radiation (28). Although the mechanism(s) by which sur-
vivin, and possibly other IAPs, localize to mitochondria is current-
ly not known, their lack of a recognizable mitochondrial import 
sequence suggests a potential role of an associated protein(s) with 
mitochondrial shuttling function. An attractive candidate for this 
pathway is the molecular chaperone Hsp90 (29), which participates 
in mitochondrial import of client proteins (30), associates with 
survivin (31) and other IAPs (our unpublished observations) in 
vivo, and exhibits an approximately 100-fold increased affinity for 
its client proteins in tumor cells (32), where survivin is abundantly 
found in mitochondria (this study). Conversely, survivin was not 
present in mitochondrial fractions of normal tissues, which sug-
gests that its localization to mitochondria may be preferentially, or 
exclusively, associated with oncogenic transformation.
An intriguing feature of mitochondrial survivin is its dynamic 
expansion in response to cellular stress, which is in keeping with an 
emerging role of IAPs in the cellular adaptation to stress. Accord-
ingly, exposure to chemotherapeutic drugs (33), exposure to heat 
shock (31), and exposure to hypoxia (19) have all been associated 
with increased IAP expression. For survivin, this appears to involve 
increased protein stability, and to result largely, if not exclusively, 
in an expansion of the mitochondrial pool. This may be envisioned 
as an adaptive response to environmental stresses, ideally suited to 
further elevate an antiapoptotic threshold in transformed cells.
As might have been predicted from its localization to the inter–
mitochondrial membrane space, survivin, unlike Bcl-2 family 
proteins (3), did not affect the release of Smac or cytochrome c 
after cell death stimulation (4, 5). Rather, mitochondrial survivin 
exerted its cytoprotective function in the cytosol upon release from 
mitochondria during apoptosis. The kinetics of survivin release 
from mitochondria, with more than 70% of the protein discharged 
in the cytosol within 4 hours of apoptotic stimulation, closely 
mirror the time course of permeability transition (4, 5). This sug-
gests a model in which loss of mitochondrial membrane integrity 
following cell death stimulation would result in the release not 
only of cell death amplifiers (18, 34, 35), but also of at least 1 cell 
death antagonist, i.e., survivin, ideally positioned to limit apop-
tosome-associated caspase activation. A critical feature of this 
pathway is that mitochondrial survivin is specifically competent 
to inhibit apoptosis, whereas overexpression of cytosolic survivin 
that cannot localize to mitochondria, i.e., in INS-1 cells, is unable 
to mediate cytoprotection. The idea that mitochondrial survivin 
could associate with Smac (21) and sequester it away from other 
IAP proteins, i.e., XIAP, in a mechanism that would be expected 
Figure 7
Mitochondrial release of survivin during apoptosis. (A) Effect on cytochrome c release. INS-1 cells stably transfected with MT-GFP or MT-S were 
treated with staurosporine, harvested at the indicated time intervals, and analyzed by immunoblotting. (B) Fluorescence microscopy. INS-1/MT-S 
cells were treated with staurosporine and analyzed for cytosolic redistribution of GFP. (C) Single-cell analysis. Areas corresponding to mitochon-
dria (yellow squares) or cytosol (gray circles) were quantitatively analyzed for changes in fluorescence distribution before (None) or after stauro-
sporine treatment (left panel). Right panel: Quantification of single-cell analysis. Changes in fluorescence intensity in individual mitochondrial or 
cytosolic areas were analyzed in the presence or absence of staurosporine treatment. Data represent an average of 16 individual determinations 
for mitochondrial areas and 14 individual determinations for cytosolic areas. (D) Time course of mitochondrial release of survivin during cell death. 
INS-1/MT-S cells were treated with staurosporine, and isolated mitochondrial or cytosolic fractions were analyzed at the indicated time intervals 
by immunoblotting. Right panel: Densitometric quantification of time-dependent depletion of mitochondrial survivin in response to staurosporine.
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to remove its pro-apoptotic function (18), appears inconsistent 
with our findings that mitochondrial survivin does not reduce 
the association of Smac with XIAP during apoptosis. Conversely, 
it is possible that posttranslational modification(s) either within 
mitochondria or in cytosolic survivin may, respectively, enable or 
prevent its cytoprotective function. In this context, one attractive 
possibility consistent with recent results (36) is that mitochondrial 
shuttling of survivin promotes its ability to associate with XIAP, 
thus facilitating increased protein stability and synergistic sup-
pression of caspase-9 (36). Further studies will test this possibility 
and delineate the structure-function requirements of cytoprotec-
tion by mitochondrial versus cytosolic survivin.
The biological context of the pathway described here is highlight-
ed by the nearly ubiquitous overexpression of survivin in cancer, as 
opposed to normal tissues (22). In tumors, survivin is expressed 
at all cell cycle phases, thus making unlikely a sole role at mito-
sis, and it correlates with clinical phenotypes typically associated 
with apoptosis resistance, including low apoptotic index, resis-
tance to therapy, and accelerated relapses (8). Nevertheless, it has 
been debated whether the high levels of survivin in cancer patients 
reflect exploitation of its mitotic function, somehow to override 
cell division checkpoints, or rather its second role in apoptosis inhi-
bition. The data obtained here with differentially transfected INS-1 
cells conclusively demonstrate that tumors selectively exploit the 
antiapoptotic function of survivin. Accordingly, targeting survivin 
to mitochondria was sufficient, alone, to enhance colony forma-
tion in soft agar, accelerate tumor growth in immunocompromised 
animals, and nearly completely ablate tumor cell apoptosis in vivo. 
Conversely, in stark contrast to the antiapoptotic gain afforded by 
mitochondrial survivin, increased expression of survivin that could 
not be transported to mitochondria, i.e., in INS-1 cells, not only 
did not contribute to tumorigenesis but actually severely impaired 
anchorage-independent cell growth, retarded tumor formation, 
and resulted in increased apoptosis in vivo. These data may be 
explained by an exaggerated function of survivin at mitosis, which 
is known to cause deregulated stability of spindle microtubules 
(10), and spindle checkpoint activation (37), leading to cell cycle 
delays and/or apoptosis. Because of its inhibition of apoptosome-
associated caspase activity, survivin cytoprotection is ideally posi-
tioned to thwart cell death pathways typically activated in tumors, 
including oncogene-, chemotherapy-, or radiation therapy–medi-
ated apoptosis (38, 39), and to accelerate and/or facilitate the acqui-
sition of additional cancer traits (1), thus furthering tumor pro-
gression. This may explain the increased mitotic index of tumors 
expressing mitochondrial survivin, which may reflect oncogenic 
changes in key cell proliferation pathway(s).
In summary, the data presented here establish survivin as a bona 
fide antiapoptotic mediator of cancer progression and validate its 
importance as a therapeutic target (8). Because of its now estab-
lished direct link to the apoptotic machinery, molecular antago-
nists of mitochondrial survivin may provide a desirable therapeutic 
window by selectively disabling tumor-associated cytoprotection 
without affecting the viability of normal tissues, where survivin is 
largely undetectable and its mitochondrial pool is not observed. 
Experimentally, this could be exemplified by the lack of toxicity of 
survivin ablation in INS-1 cells, as opposed to the robust apoptosis 
observed in MCF-7 cells (20). Because survivin is a short-lived pro-
tein at cell division, such an approach may not interfere with the 
mitotic function of survivin and may thus further limit toxicity for 
highly proliferating normal cellular compartments, which are typi-
cally compromised by conventional anticancer regimens. Therefore, 
these distinctive features of the survivin pathway provide a unique 
opportunity for rational anticancer treatment in humans (8).
Methods
Cell lines and antibodies. Breast carcinoma MCF-7, cervical carcinoma HeLa, 
colorectal carcinoma HCT116, B lymphoma Raji, and human embryonic 
kidney HEK293T cells were obtained from the American Type Culture Col-
lection. The rat insulinoma cell line INS-1 was the kind gift of R.S. Sherwin 
(Yale University School of Medicine, New Haven, Connecticut, USA). The 
antibodies to survivin (Novus Biologicals Inc.) were described previously 
(16). The following antibodies were also used: Aurora A (Novus Biologicals 
Inc.), Smac (1:1,000; ProSci Inc.), cytochrome c (1:1,000; BD Biosciences — 
Pharmingen), Cox-4 (1:5,000; BD Biosciences — Clontech), Bcl-2 (1:1,000; 
Santa Cruz Biotechnologies Inc.), XIAP (1:1,000; Transduction Laborato-
ries), mitochondrial Hsp70 (Affinity BioReagents Inc.), and β-actin (1:5,000, 
clone AC-15, A5441; Sigma-Aldrich). An antibody to phosphorylated eIF2α 
was obtained from Cell Signaling Technology Inc.
Generation of transfected cell lines. A human survivin cDNA containing 
BamHI sites was synthesized by PCR using the primers 5′-AGAGGT-
GGGATCCCGGCATG-3′ (forward) and 5′-AGCTCCGGATCCAGGCCTC-
Figure 8
Mechanisms of cytoprotection by mitochondrial survivin. (A) Inhibition 
of caspase-9 processing. MCF-7 cells transduced with pAd-MTGFP or 
pAd-MTS were treated with staurosporine and analyzed for caspase-9 
processing at the indicated time intervals, by immunoblotting. The 
position of approximately 37-kDa active caspase-9 is indicated. Lower 
panel: Quantification of caspase-9 generation by densitometry. (B) 
XIAP-Smac interaction. Control cultures or MCF-7 cells transduced 
with pAd-MTS were treated with staurosporine and immunoprecipitated 
with an antibody to Smac or control IgG, and pellets and supernatants 
were analyzed by immunoblotting with antibodies to XIAP or Smac.
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TA-3′ (reverse). The cDNA was inserted in-frame into the BamHI sites of 
pECFP-Mito (BD Biosciences — Clontech) to construct pECFP-mt-Sur-
vivin. INS-1 cells were transfected with control vector or mitochondrially 
targeted survivin by LipofectAMINE (Invitrogen Corp.), and transferred to 
a 100-mm dish in selection medium containing 800 μg/ml G418 (GIBCO; 
Invitrogen Corp.). Colonies were picked 2–3 weeks later and expanded, and 
mitochondrial targeting of survivin in stable cell lines was demonstrated by 
fluorescence microscopy and immunoblotting of isolated mitochondrial 
fractions (see below). Experiments were conducted with 2 independent 
clonal cell lines with identical results.
Adenoviral vectors and cellular transduction. The pAd vectors encoding Surv 
(pAd-Survivin) or GFP (pAd-GFP) have been described (40). pAd-MTS 
was established using the pAdEasy system, as described previously (40). 
To construct the shuttle vector, a cDNA encoding HA-survivin containing 
BamHI sites was synthesized by PCR using primers 5′-GGAGACCGGT-
GCTTATGTACCCAT-3′ (forward) and 5′-CATTTTATTAGGAAAGGA-
CAGTGG-3′ (reverse). The cDNA was linearized and cloned in-frame into 
the BamHI sites of pECFP-Mito to construct pECFP-mt-HA-survivin. A 
NheI-NotI fragment was isolated from pECFP-mt-HA-survivin or pECFP-
Mito and subcloned into pBluescript II KS(+) (Stratagene) to generate 
pBluescript-mtHAsurvivin or pBluescript-mtCFP, and a SalI-NotI frag-
ment was subcloned into pAdTrack-CMV to generate pAd-MTS or pAd-
MTCFP. Each shuttle vector was linearized with PmeI and electroporated 
in Escherichia coli BJ5183 for homologous recombination, and colonies were 
selected in 50 μg/ml kanamycin. Each pAd construct (4–8 μg) was digested 
with PacI and transfected in HEK293T cells by LipofectAMINE, and cul-
tures were monitored for expression of GFP by fluorescence microscopy. 
High-titer viral stocks were generated as described previously (40) and 
Figure 9
Mitochondrial survivin promotes tumorigenicity. (A) Colony formation in soft agar. Differentially transfected INS-1 cells were plated in semisolid 
medium and scored for colony formation by phase-contrast microscopy. (B) Quantification of colony formation in soft agar. The experimental con-
ditions were as in A. Data are the mean ± SD of a representative experiment of at least 2 independent determinations. ***P = 0.0001. (C) Kinetics 
of tumor growth. Stably transfected INS-1 cells were injected subcutaneously in the flank of CB17 SCID/beige mice, and tumor volume was deter-
mined at the indicated time intervals. Statistical analysis compared growth of INS-1/Surv versus INS-1/MT-S tumors at day 28 (P = 0.024), day 35 
(P = 0.0069), and day 45 (P = 0.015). *P < 0.05; **P < 0.01. (D) Histology. Tissue sections from the indicated INS-1 tumors were stained by H&E, 
Ki67 reactivity as a measure of cell proliferation, and TUNEL as a measure of apoptosis, in vivo. Magnification, ×400. (E) Mitotic index in vivo. The 
number of Ki67-positive (proliferating) cells was counted in 7 independent fields, each containing an average of 400 cells. #P = 0.031. (F) Apoptotic 
index in vivo. The number of TUNEL-positive (apoptotic) cells was counted in 7 independent fields, each containing an average of 400 cells.
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purified by CsCl banding, and viral titer was quantified by green fluores-
cence–forming units in HEK293T cells infected with serial dilution of the 
viral stock. Cultures were transduced at a multiplicity of infection of 50 
for 8 hours at 37°C in complete medium, washed with PBS, pH 7.4, and 
replenished with complete medium. The transduction efficiency (>90% of 
the cell population) was estimated from GFP fluorescence.
Preparation of mitochondrial and cytosolic extracts. Mitochondrial and 
cytosolic fractions were extracted from MCF-7 cells (6 × 107 to 7 × 107) 
or INS-1 cells (7 × 107 to 8 × 107) using the ApoAlert Cell Fractionation 
Kit (BD Biosciences — Clontech), according to the supplier’s instruc-
tions. The isolated cytosolic fraction was further centrifuged at 10,000 
g for 25 minutes at 4°C, and the supernatant was collected. Alterna-
tively, mitochondrial extracts were prepared from MCF-7 or INS-1 cells 
(5 × 107) washed in TD buffer (135 mM NaCl, 5 mM KCl, 25 mM Tris-
Cl, pH 7.6) and allowed to swell for 10 minutes in ice-cold hypotonic 
CaRSB buffer (10 mM NaCl, 1.5 mM CaCl2, 10 mM Tris-HCl, pH 7.5, 
plus protease inhibitors). Cells were Dounce-homogenized with 70 
strokes, with addition of MS buffer (210 mM mannitol, 70 mM sucrose, 
5 mM Tris, pH 7.6) to stabilize mitochondria (2 ml of 2.5× per 3 ml 
of homogenate). After removal of nuclear contaminants by centrifuga-
tion at 600 g for 15 minutes on ice, the supernatants were layered over a 
1- to 2-M sucrose step gradient (10 mM Tris, 5 mM EDTA, pH 7.6, 2 mM 
DTT, plus protease inhibitors) and centrifuged at 110,000 g for 30 min-
utes at 4°C. Mitochondria were collected at the 1- to 1.5-M interphase 
by lateral suction through the tube, washed in 4 volumes of MS buffer 
at 9,400 g, and suspended in a final volume of 200 μl of MS buffer. The 
top layer, containing a cytosolic and a free protein fraction, was collected 
and used in parallel experiments. The purity of mitochondrial fractions 
was examined by immunoblotting with antibodies to mitochondrial 
Cox-4 or cytosolic Aurora A. In some experiments, testis, spleen, and 
liver isolated from 5-week-old FVB/N mice were fractionated in cytosolic 
and mitochondrial extracts using a Mitochondria Isolation Kit (Sigma-
Aldrich), according to the manufacturer’s specifications.
Electron microscopy. MCF-7 cell pellets or isolated mitochondrial frac-
tions prepared by sucrose gradient ultracentrifugation were fixed in 3% 
formaldehyde and 0.1% glutaraldehyde (EM grade) for 10 minutes at 
37°C. Samples were incubated in 50 mM NH4Cl in PBS for 60 minutes 
at 22°C to aminidate free aldehydes, dehydrated through a gradual 
series of ethanol to 100%, and transferred into a mixture of 50:50 (vol/
vol) Lowicryl K4M resin/100% ethanol overnight at 22°C. Samples were 
transferred to aliquots of fresh resin (3 changes, 1 hour each) and applied 
to filling embedding capsules for 24 hours at 60°C. Thin sections were 
cut using a diamond knife on a Reichert-Jung Ultracut E ultramicro-
tome and placed on gold support grids for immunostaining. For label-
ing, sections were incubated in blocking solution (Zymed Laboratories 
Inc.) for 30 minutes at 22°C, rinsed, incubated with primary antibodies 
to survivin, Smac, or control IgG, rinsed again, and incubated with gold-
conjugated secondary reagents (Smac, 6 nm diameter; survivin, 12 nm 
diameter) of appropriate specificities (1:20; Jackson ImmunoResearch 
Laboratories Inc.). After washes, samples were exposed to OsO4 vapor 
for 1 hour at 22°C, post-stained with uranyl acetate and lead citrate, and 
analyzed on a Philips CM10 electron microscope (Philips Electronics) at 
80 kV. For quantification of mitochondrial colocalization of survivin 
and Smac, 19 individual electron microscopy fields containing an aver-
age of 2.9 mitochondria each were individually scored for accumulation 
of survivin- and Smac-associated gold particles.
Fluorescence microscopy. INS-1 stable transfectants were plated onto 35-mm 
glass-bottom culture dishes with grid (MatTek Corp.). After 24 hours, cells 
were treated with staurosporine (Sigma-Aldrich), washed with PBS, and 
scanned with a manual/motorized reflected-fluorescence system (Olympus 
Corp.) at increasing time intervals after induction of apoptosis. Collected 
images were analyzed with IPLab version 3.5.4 software (Scanalytics Inc.). 
To quantify translocation of the GFP signal during apoptosis, 264 individ-
ual INS-1 cells stably transfected with mitochondrially targeted survivin 
(INS-1/MT-S) were scored for changes in GFP localization before or after 
staurosporine treatment. In single-cell analysis, regions corresponding to 
mitochondria or cytosol were analyzed for changes in fluorescence distri-
bution before or after staurosporine treatment.
Mitochondrial sublocalization studies. Mitochondrial or cytosolic extracts 
were incubated in MS buffer in the presence of 0–30 ng/ml proteinase K 
(Sigma-Aldrich) for 10 minutes at 0°C, and the reaction was stopped by 
addition of protease inhibitors. Modulation of survivin or Bcl-2 protein 
levels was monitored by immunoblotting. For differential extraction of 
mitochondrial proteins, freshly isolated mitochondrial pellets were incu-
bated with increasing concentrations (0–4%) of digitonin (Sigma-Aldrich) 
for 15 minutes at 0°C. Pellets and supernatants were analyzed for differen-
tial redistribution of survivin or Smac proteins, by immunoblotting. Reac-
tivity with nonextractable mitochondrial Hsp70 was used as control. The 
concentrations of digitonin used have been previously shown to extract 
proteins from the outer mitochondrial membrane (17).
Modulation of mitochondrial survivin during the cellular stress response. For mod-
ulation of survivin expression and distribution during hypoxia, HeLa cells 
(2.5 × 105) were seeded in 35-mm-diameter tissue culture dishes. Cells were 
washed 3 times in PBS and incubated for 6 hours in KRB buffer (115 mM 
NaCl, 1 mM KH2PO4, 4 mM KCl, 1 mM MgSO4, 1.25 mM CaCl2, 27 mM 
NaHCO3) containing 1.2 U/ml Oxyrase (Oxyrase Inc.), in a GasPak 100 anaer-
obic chamber (BD). Whole cell extracts or isolated mitochondrial or cytosolic 
fractions were analyzed by immunoblotting. Control cells were incubated in 
KRB buffer alone. For cycloheximide block experiments, control or hypoxic 
HeLa cells were treated with cycloheximide (100 μg/ml), harvested after 2–6 
hours, analyzed by immunoblotting, and quantified by β-actin–normalized 
densitometry. Alternatively, MCF-7 cells were treated with the chemothera-
peutic drug adriamycin (100 nM), and isolated cytosolic or mitochondrial 
fractions were analyzed after 24 hours by immunoblotting.
Cell death analysis. Subconfluent cultures of parental or transfected/
transduced INS-1 or MCF-7 cells were exposed to staurosporine (0.1–1 
μM), UVB irradiation (50–100 J/m2), or growth factor deprivation (0% 
FCS for 96 hours), harvested at increasing time intervals, and analyzed 
for hypodiploid DNA content by propidium iodide staining and flow 
cytometry. Alternatively, cells exposed to the various cell death stimuli 
were harvested, fixed in 4% paraformaldehyde containing 4% sucrose for 
10 minutes at 22°C, and analyzed for nuclear morphology of apoptosis by 
staining with 6.5 μg/ml DAPI (Sigma-Aldrich) in 16% polyvinyl alcohol (Air 
Products and Chemicals Inc.) and 40% glycerol. In some experiments, the 
pan-caspase inhibitor zVAD-fmk (Enzyme Systems Products Inc.) was used 
(20 μM). For caspase activity, cells exposed to cell death stimuli were simul-
taneously analyzed for caspase activity and propidium iodide staining by 
multiparametric flow cytometry using the CaspaTag caspase-3 activity kit 
(Intergen Co.), or analyzed by immunoblotting using antibodies to acti-
vated caspase-3 or -9 (1:1,000; Transduction Laboratories). Acute ablation 
of survivin in MCF-7 or INS-1 cells was carried out by RNAi using the S4 
dsRNA oligonucleotide GAGCCAAGAACAAAAUUGC, as described previ-
ously (20). Unrelated dsRNA oligonucleotide VIII was used as control (20). 
Cultures were analyzed for loss of survivin protein by immunoblotting, 
and analyzed for cell viability and mitotic defects by DNA content and flow 
cytometry. To determine the potential impact of mitochondrial survivin 
on the formation of a Smac-XIAP complex, MCF-7 cells were transduced 
with pAd-MTS, exposed to staurosporine, and immunoprecipitated with 
an antibody to Smac or control IgG. The immune complexes were probed 
with antibodies to XIAP or Smac, by immunoblotting.
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Analysis of tumorigenesis. For soft agar colony formation, 2 × 104 stable INS-1 
transfectants were suspended in 1.5 ml of DMEM supplemented with 10% 
FBS and 0.35% bactoagar (BD) in 36-mm tissue culture plates contain-
ing 1.5 ml of 0.75% agarose in growth medium at the bottom layer. The 
plates were incubated at 37°C in a 5% CO2 incubator for 2 weeks. Colonies 
were stained with 0.005% crystal violet (Sigma-Aldrich), and counted using 
a dissecting microscope under high-power field. Experiments were con-
ducted with 2 independent INS-1 clones with identical results. All experi-
ments involving animals were approved by the institutional animal care 
and use committee. For xenograft tumor formation experiments, 2.5 × 106 
INS-1 stable transfectants were injected into the flanks of 6- to 8-week-old 
female CB17 SCID/beige mice (Taconic; 3 animals per group, 2 tumors per 
animal). Tumor volume was measured in the 3 dimensions with a caliper 
at the indicated time intervals after injection. An independent experiment 
of tumor formation was repeated with 4 animals per group (2 tumors per 
animal) with identical kinetics of tumor growth.
Histology. All tissue specimens were fixed in buffered formalin and 
embedded in paraffin. For tissue staining, sections were deparaffinized, 
rehydrated in water, and quenched for endogenous peroxidase. Epitope 
heat retrieval was carried out by steaming of the slides in 10% sodium 
citrate for 60 minutes. Processed slides were rinsed in PBS, and stained 
using standard avidin-biotin-peroxidase technique using the Histostain-
Plus kit (Zymed Laboratories Inc.). After blocking, tissue sections were 
incubated overnight at 4°C with antibody Ki67 (1:25; DAKO Inc.), rinsed, 
and incubated with biotinylated anti-mouse IgG for 10 minutes at 22°C. 
Following addition of streptavidin-conjugated HRP, slides were incubated 
with 3′-3′-diamino-benzidine (DAB) as a chromogen and counterstained 
with hematoxylin. Negative control sections were processed as above with-
out primary antibody and resulted in no detectable staining. A mitotic 
index was derived from the percentage of Ki67-positive cells counted 
under high-power field. For determination of internucleosomal DNA 
fragmentation by TUNEL staining, tissue sections were processed using 
the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Chemicon Inter-
national Inc.), according to the supplier’s specifications. An apoptotic 
index was calculated from the percentage of TUNEL-positive cells count-
ed under high-power fields.
Statistical analysis. Data were analyzed using the unpaired t test on a 
GraphPad Prism software package for Windows (GraphPad Software 
Inc.). A P value of 0.05 was considered statistically significant.
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